Xradia

Xradia specializes in advanced imaging solutions, providing innovative X-ray microscopy systems that enable detailed analysis of materials and biological specimens. Founded in 2000 and headquartered in Pleasanton, US, Xradia focuses on developing X-ray imaging technologies. The company was acquired by Carl Zeiss Group in June 2013 for an undisclosed sum. Throughout its history, Xradia has completed three major investment deals, with the latest funding round being a Series D in which it raised USD 5.

00 mn, led by 180 Degree Capital and Intel Capital. The current company valuation stands at USD 33. 01 mn. Xradia provides cutting-edge X-ray microscopy systems designed for high-resolution imaging of materials and biological samples.

Their products cater to various applications in research and industrial settings, aiming to enhance the capabilities of scientists and engineers in material analysis and biological studies. Xradia generates revenue through the sale of its X-ray imaging systems and related services, focusing on providing high-quality solutions that meet the needs of its diverse client base in research and industry. Xradia plans to leverage its recent funding to enhance its product offerings and expand its market presence. Following the acquisition by Carl Zeiss Group, the company aims to release new imaging solutions tailored for advanced research applications.

Specific details on the release dates for these new products have not been disclosed. Additionally, the company is exploring opportunities to expand into new geographic regions to increase its customer base and market penetration.